Search hospitals > Ohio > Columbus
Arthur G. James Cancer Hospital - Ohio State University
Claim this profileColumbus, Ohio 43202
Global Leader in Lymphoma
Global Leader in Adult T-Cell Leukemia/Lymphoma
Conducts research for Lung Cancer
Conducts research for Breast Cancer
Conducts research for Leukemia
491 reported clinical trials
16 medical researchers
Summary
Arthur G. James Cancer Hospital - Ohio State University is a medical facility located in Columbus, Ohio. This center is recognized for care of Lymphoma, Adult T-Cell Leukemia/Lymphoma, Lung Cancer, Breast Cancer, Leukemia and other specialties. Arthur G. James Cancer Hospital - Ohio State University is involved with conducting 491 clinical trials across 360 conditions. There are 16 research doctors associated with this hospital, such as Uma Borate, MD, Alice Mims, Sagar Sardesai, MD, and David O'Malley, MD.Area of expertise
1Lymphoma
Global LeaderStage IV
Stage III
CCND1 positive
2Adult T-Cell Leukemia/Lymphoma
Global LeaderFLT3 positive
SF3B1 positive
U2AF1 positive
Top PIs
Uma Borate, MDOhio State University Comprehensive Cancer Center3 years of reported clinical research
Studies Adult T-Cell Leukemia/Lymphoma
Studies Acute Myeloid Leukemia
17 reported clinical trials
31 drugs studied
Alice MimsOhio State University Comprehensive Cancer Center6 years of reported clinical research
Expert in Adult T-Cell Leukemia/Lymphoma
Expert in Acute Myeloid Leukemia
19 reported clinical trials
42 drugs studied
Sagar Sardesai, MDOhio State University Comprehensive Cancer Center1 year of reported clinical research
Expert in Breast Cancer
Studies Lobular Carcinoma in Situ
14 reported clinical trials
25 drugs studied
David O'Malley, MDOhio State University Comprehensive Cancer Center2 years of reported clinical research
Studies Ovarian Cancer
Studies Serous Cystadenocarcinoma
12 reported clinical trials
27 drugs studied
Clinical Trials running at Arthur G. James Cancer Hospital - Ohio State University
Acute Myeloid Leukemia
Myelofibrosis
Lymphoma
Multiple Myeloma
Adult T-Cell Leukemia/Lymphoma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Breast Cancer
Acute Myelogenous Leukemia
SGR-2921
for Leukemia and Preleukemia
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Recruiting1 award Phase 1
SEA-CD70
for Myelodysplastic Syndrome and Acute Myeloid Leukemia
This trial is testing a new drug, SEA-CD70, alone and with azacitidine, to see if it is safe and works for adults with certain blood cancers that haven't responded to other treatments. The study will determine the best dose and check for side effects. Azacitidine is a treatment that improves survival, reduces the need for transfusions, and lowers the risk of progression to acute myeloid leukemia in patients with higher risk myelodysplastic syndromes.
Recruiting1 award Phase 110 criteria
Emavusertib (+ Venetoclax)
for Acute Myeloid Leukemia
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study: * Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor * R/R AML with spliceosome mutations of splicing factor 3B subunit 1 (SF3B1) or U2AF1 * R/R hrMDS with spliceosome mutations of SF3B1 or U2 small nuclear RNA auxiliary factor 1 (U2AF1) * Number of pretreatments: 1 or 2 The Phase 2a Dose Expansion will be in 3 Cohorts of patients: 1. R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor; 2. R/R AML with spliceosome mutations of SF3B1 or U2AF1; and 3. R/R hrMDS (Revised International Prognostic Scoring System \[IPSS-R\] score \> 3.5) with spliceosome mutations of SF3B1 or U2AF1. All patients above have had ≤ 2 lines of prior systemic anticancer treatment. In previous versions of this protocol there was a Phase 1b portion of the study, in which patients with AML or hrMDS received CA-4948 in combination with venetoclax. This part of the study is no longer open for enrollment.
Recruiting1 award Phase 1 & 29 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Arthur G. James Cancer Hospital - Ohio State University?
Where is Arthur G. James Cancer Hospital - Ohio State University located?
Who should I call to ask about financial aid or insurance network?
What insurance does Arthur G. James Cancer Hospital - Ohio State University accept?
What awards or recognition has Arthur G. James Cancer Hospital - Ohio State University received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.